Novo Nordisk A/S’s Price-to-Earnings Ratio at a glance
Novo Nordisk A/S reports price-to-earnings ratio of 27.5x for Dec 2024. The prior period recorded 37.4x (Dec 2023). Year over year the metric moved −9.87 (−26.4%). The rolling three-period average stands at 34.4x. Data last refreshed Dec 7, 2025, 2:48 AM.
Latest reading
27.5x · Dec 2024
YoY movement
−9.87 (−26.4%)
Rolling average
34.4x
Current Price-to-Earnings Ratio
27.5x
−9.87
−26.4%
Rolling average
34.4x
Latest Value
27.5x
Dec 2024
YoY Change
−9.87
Absolute
YoY Change %
−26.4%
Rate of change
3-Period Avg
34.4x
Smoothed
Narrative signal
Novo Nordisk A/S’s price-to-earnings ratio stands at 27.5x for Dec 2024. Year-over-year, the metric shifted by −9.87, translating into a −26.4% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How price-to-earnings ratio shapes Novo Nordisk A/S's story
As of Dec 2024, Novo Nordisk A/S reports price-to-earnings ratio of 27.5x. Analyze price-to-earnings history, valuation swings, and relative multiples to benchmark market expectations.
Why the P/E ratio matters
The price-to-earnings multiple reveals how much investors are willing to pay for each dollar of net income. Elevated P/E levels suggest strong growth expectations or limited earnings.
Tracking valuation cycles
Monitoring multi-year P/E trends highlights how macro cycles, product launches, or profitability changes impact valuation over time.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Gross Margin
84.7%
Operating Margin
44.2%
Net Profit Margin
34.8%
Return on Equity
70.4%
Return on Assets
21.7%
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Novo Nordisk A/S (NVO) FAQs
Answers tailored to Novo Nordisk A/S’s price-to-earnings ratio profile using the latest Financial Modeling Prep data.
What is Novo Nordisk A/S's current price-to-earnings ratio?
As of Dec 2024, Novo Nordisk A/S reports price-to-earnings ratio of 27.5x. This reading reflects the latest filings and price data for NVO.
How is Novo Nordisk A/S's price-to-earnings ratio trending year over year?
Year-over-year, the figure shifts by −9.87 (−26.4%). Pair this context with revenue growth and free cash flow signals to gauge momentum for NVO.
Why does price-to-earnings ratio matter for Novo Nordisk A/S?
The P/E ratio compares a company’s share price with its per-share earnings to gauge valuation. For Novo Nordisk A/S, operating within Healthcare — Drug Manufacturers - General, tracking this metric helps benchmark management's execution against close competitors.
Is Novo Nordisk A/S's price-to-earnings ratio above its recent average?
Novo Nordisk A/S's rolling three-period average sits at 34.4x. Comparing the latest reading of 27.5x to that baseline highlights whether momentum is building or fading for NVO.
How frequently is Novo Nordisk A/S's price-to-earnings ratio refreshed?
Data for NVO was last refreshed on Dec 7, 2025, 2:48 AM and updates automatically every 24 hours, keeping your valuation inputs current.